康哲药业(00867)获得1类新药MG-K10人源化单抗注射液新增慢性阻塞性肺疾病适应症药物临床试验批准通知书

Core Viewpoint - Kangzheng Pharmaceutical (00867) has received approval from the National Medical Products Administration (NMPA) for clinical trials of its new drug MG-K10, a humanized monoclonal antibody targeting IL-4Rα, for the treatment of chronic obstructive pulmonary disease (COPD) [1] Group 1 - The company holds co-development rights (excluding atopic dermatitis) and exclusive commercialization rights for the new drug MG-K10 [1] - The NMPA issued the drug clinical trial approval notice on September 29, 2025 [1] - The clinical trial will focus on the application of MG-K10 in treating COPD [1]